AU2019224121B2 - Compositions and methods for treating non-age-associated hearing impairment in a human subject - Google Patents
Compositions and methods for treating non-age-associated hearing impairment in a human subjectInfo
- Publication number
- AU2019224121B2 AU2019224121B2 AU2019224121A AU2019224121A AU2019224121B2 AU 2019224121 B2 AU2019224121 B2 AU 2019224121B2 AU 2019224121 A AU2019224121 A AU 2019224121A AU 2019224121 A AU2019224121 A AU 2019224121A AU 2019224121 B2 AU2019224121 B2 AU 2019224121B2
- Authority
- AU
- Australia
- Prior art keywords
- amino acids
- acid substitutions
- amino acid
- amino
- sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
- A01K67/0276—Knock-out vertebrates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0046—Ear
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
- A61K9/5153—Polyesters, e.g. poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/65—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression using markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/103—Ovine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/0306—Animal model for genetic diseases
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/40—Systems of functionally co-operating vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/48—Vector systems having a special element relevant for transcription regulating transport or export of RNA, e.g. RRE, PRE, WPRE, CTE
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/50—Vector systems having a special element relevant for transcription regulating RNA stability, not being an intron, e.g. poly A signal
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/44—Vectors comprising a special translation-regulating system being a specific part of the splice mechanism, e.g. donor, acceptor
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Environmental Sciences (AREA)
- Virology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- Optics & Photonics (AREA)
- Nanotechnology (AREA)
- Biodiversity & Conservation Biology (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2025263792A AU2025263792A1 (en) | 2018-02-22 | 2025-11-05 | Compositions and methods for treating non-age-associated hearing impairment in a human subject |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862634088P | 2018-02-22 | 2018-02-22 | |
| US62/634,088 | 2018-02-22 | ||
| PCT/US2019/019268 WO2019165292A1 (en) | 2018-02-22 | 2019-02-22 | Compositions and methods for treating non-age-associated hearing impairment in a human subject |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2025263792A Division AU2025263792A1 (en) | 2018-02-22 | 2025-11-05 | Compositions and methods for treating non-age-associated hearing impairment in a human subject |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2019224121A1 AU2019224121A1 (en) | 2020-08-27 |
| AU2019224121B2 true AU2019224121B2 (en) | 2025-08-07 |
Family
ID=67687298
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2019224121A Active AU2019224121B2 (en) | 2018-02-22 | 2019-02-22 | Compositions and methods for treating non-age-associated hearing impairment in a human subject |
| AU2025263792A Pending AU2025263792A1 (en) | 2018-02-22 | 2025-11-05 | Compositions and methods for treating non-age-associated hearing impairment in a human subject |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2025263792A Pending AU2025263792A1 (en) | 2018-02-22 | 2025-11-05 | Compositions and methods for treating non-age-associated hearing impairment in a human subject |
Country Status (15)
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018039375A1 (en) | 2016-08-23 | 2018-03-01 | Akouos, Inc. | Compositions and methods for treating non-age-associated hearing impairment in a human subject |
| US12359221B2 (en) | 2017-05-05 | 2025-07-15 | The Regents Of The University Of California | Compositions and methods for expressing otoferlin |
| IL325122A (en) | 2018-02-22 | 2026-02-01 | Akouos Inc | Compositions and methods for treating non-age-related hearing impairment in humans |
| US11660353B2 (en) | 2018-04-27 | 2023-05-30 | Decibel Therapeutics, Inc. | Compositions and methods for treating sensorineural hearing loss using otoferlin dual vector systems |
| CN112703016B (zh) | 2018-04-27 | 2024-11-22 | 分贝治疗公司 | 肌球蛋白15启动子及其用途 |
| CN113924109A (zh) | 2019-01-18 | 2022-01-11 | 巴斯德研究所 | Aav介导的基因疗法恢复耳畸蛋白基因 |
| EP3921032A4 (en) | 2019-02-08 | 2022-11-30 | Decibel Therapeutics, Inc. | COMPOSITIONS AND METHODS FOR TREATMENT OF SENSORINEURAL HEARING LOSS USING OTOFERLIN DOUBLE VECTOR SYSTEMS |
| WO2020163761A1 (en) | 2019-02-08 | 2020-08-13 | Decibel Therapeutics, Inc. | Myosin 15 promoters and uses thereof |
| EP4007814A1 (en) | 2019-07-26 | 2022-06-08 | Akouos, Inc. | Methods of treating hearing loss using a secreted target protein |
| TWI896570B (zh) | 2019-10-30 | 2025-09-11 | 美商迪賽博治療公司 | 使用耳畸蛋白雙載體系統治療感覺神經性聽力損失之組合物及方法 |
| CA3168055A1 (en) * | 2020-02-21 | 2021-08-26 | Emmanuel John Simons | Compositions and methods for treating non-age-associated hearing impairment in a human subject |
| IL295741A (en) | 2020-04-01 | 2022-10-01 | Univ Florida | Dual aav-myo7a vectors with improved safety for the treatment of ush1b |
| KR20230041965A (ko) | 2020-05-13 | 2023-03-27 | 아카우오스, 인크. | Slc26a4-연관 청력손실을 치료하기 위한 조성물 및 방법 |
| CN117157108A (zh) | 2020-12-29 | 2023-12-01 | 阿库斯股份有限公司 | 用于治疗clrn1相关听力损失和/或视力损失的组合物和方法 |
| KR20240004253A (ko) * | 2021-02-19 | 2024-01-11 | 데시벨 테라퓨틱스, 인크. | 오토펄린 듀얼 벡터 시스템을 사용한 감각신경성 난청을 치료하기 위한 방법 |
| CN113063944B (zh) * | 2021-03-05 | 2023-03-24 | 李朴 | 血清gsdme在b淋巴细胞白血病诊断、疗效监测及预后评估上的用途 |
| CN113337507B (zh) * | 2021-08-05 | 2021-11-12 | 首都医科大学附属北京友谊医院 | Otof 1273 (C>T)基因定点突变的耳聋小鼠模型的构建方法及其应用 |
| JP2024534991A (ja) * | 2021-09-10 | 2024-09-26 | インスティチュート パスツール | オトフェリンのアイソフォーム5をコードする二重組換えaav8ベクター系およびその使用 |
| CN114807224B (zh) * | 2022-04-25 | 2023-09-29 | 中国人民解放军军事科学院军事医学研究院 | 一种可视化斑马鱼胆汁酸代谢模型的构建方法及其应用 |
| CN114854762A (zh) * | 2022-06-09 | 2022-08-05 | 上海鼎新基因科技有限公司 | 编码人otof的核酸序列及其应用 |
| CN115141896A (zh) * | 2022-09-04 | 2022-10-04 | 上海鼎新基因科技有限公司 | 一种AAV组织分布的qPCR检测方法 |
| CN116925239B (zh) * | 2023-07-17 | 2024-10-18 | 苏州星奥拓维生物技术有限公司 | 双载体系统表达Otof基因的组合物和方法 |
| CN117305367A (zh) * | 2023-08-21 | 2023-12-29 | 复旦大学附属眼耳鼻喉科医院 | 一种表达全长耳畸蛋白的双aav载体系统及其应用 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016139321A1 (en) * | 2015-03-03 | 2016-09-09 | Fondazione Telethon | Multiple vector system and uses thereof |
| WO2018039375A1 (en) * | 2016-08-23 | 2018-03-01 | Akouos, Inc. | Compositions and methods for treating non-age-associated hearing impairment in a human subject |
Family Cites Families (172)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH587021A5 (cg-RX-API-DMAC10.html) | 1974-06-07 | 1977-04-29 | Nestle Sa | |
| EP0173552B1 (en) | 1984-08-24 | 1991-10-09 | The Upjohn Company | Recombinant dna compounds and the expression of polypeptides such as tpa |
| US5168062A (en) | 1985-01-30 | 1992-12-01 | University Of Iowa Research Foundation | Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence |
| US5651991A (en) | 1987-10-28 | 1997-07-29 | Nippon Shinyaku Co. Ltd. | Drug carriers |
| US5549910A (en) | 1989-03-31 | 1996-08-27 | The Regents Of The University Of California | Preparation of liposome and lipid complex compositions |
| US5252334A (en) | 1989-09-08 | 1993-10-12 | Cygnus Therapeutic Systems | Solid matrix system for transdermal drug delivery |
| JP3218637B2 (ja) | 1990-07-26 | 2001-10-15 | 大正製薬株式会社 | 安定なリポソーム水懸濁液 |
| JP2958076B2 (ja) | 1990-08-27 | 1999-10-06 | 株式会社ビタミン研究所 | 遺伝子導入用多重膜リポソーム及び遺伝子捕捉多重膜リポソーム製剤並びにその製法 |
| CA2091152C (en) | 1993-03-05 | 2005-05-03 | Kirsten Westesen | Solid lipid particles, particles of bioactive agents and methods for the manfuacture and use thereof |
| JPH07285863A (ja) | 1994-02-25 | 1995-10-31 | Takeda Chem Ind Ltd | 注射剤組成物およびその製造方法 |
| ES2078190B1 (es) | 1994-05-20 | 1996-08-01 | Cusi Lab | Procedimiento para el recubrimiento de goticulas o particulas de tamaño nanometrico. |
| US5741516A (en) | 1994-06-20 | 1998-04-21 | Inex Pharmaceuticals Corporation | Sphingosomes for enhanced drug delivery |
| US5795587A (en) | 1995-01-23 | 1998-08-18 | University Of Pittsburgh | Stable lipid-comprising drug delivery complexes and methods for their production |
| US5697899A (en) | 1995-02-07 | 1997-12-16 | Gensia | Feedback controlled drug delivery system |
| US5510118A (en) | 1995-02-14 | 1996-04-23 | Nanosystems Llc | Process for preparing therapeutic compositions containing nanoparticles |
| US5738868A (en) | 1995-07-18 | 1998-04-14 | Lipogenics Ltd. | Liposome compositions and kits therefor |
| US5656016A (en) | 1996-03-18 | 1997-08-12 | Abbott Laboratories | Sonophoretic drug delivery system |
| US5797898A (en) | 1996-07-02 | 1998-08-25 | Massachusetts Institute Of Technology | Microchip drug delivery devices |
| US5783208A (en) | 1996-07-19 | 1998-07-21 | Theratech, Inc. | Transdermal drug delivery matrix for coadministering estradiol and another steroid |
| US5779708A (en) | 1996-08-15 | 1998-07-14 | Cyberdent, Inc. | Intraosseous drug delivery device and method |
| CA2264482A1 (en) | 1996-09-06 | 1998-03-12 | The Trustees Of The University Of Pennsylvania | An inducible method for production of recombinant adeno-associated viruses utilizing t7 polymerase |
| US6007856A (en) | 1997-08-08 | 1999-12-28 | The Procter & Gamble Company | Oil-in-water dispersions of β-carotene and other carotenoids stable against oxidation prepared from water-dispersible beadlets having high concentrations of carotenoid |
| DE59914485D1 (de) | 1998-03-30 | 2007-10-18 | Mibelle Ag Cosmetics | Verwendung von Nanoemulsionen zur Bestimmung der Biokompatibilität von lipophilen Stoffen im Zellkultur-Test und dafür geeignete Nanoemulsionen |
| US6436392B1 (en) | 1998-05-20 | 2002-08-20 | University Of Iowa Research Foundation | Adeno-associated virus vectors |
| US8026096B1 (en) | 1998-10-08 | 2011-09-27 | Protein Sciences Corporation | In vivo active erythropoietin produced in insect cells |
| PT1144009E (pt) | 1998-12-03 | 2003-01-31 | Avigen Inc | Excipientes para uso em formulacoes farmaceuticas a base de virus adeno-associado e formulacoes farmaceuticas produzidas com estes excipientes |
| FR2787728B1 (fr) | 1998-12-23 | 2001-01-26 | Oreal | Nanoemulsion a base d'esters gras d'acide phosphorique, et ses utilisations dans les domaines cosmetique, dermatologique, pharmaceutique et/ou ophtalmologique |
| US6258595B1 (en) | 1999-03-18 | 2001-07-10 | The Trustees Of The University Of Pennsylvania | Compositions and methods for helper-free production of recombinant adeno-associated viruses |
| WO2001025253A2 (en) | 1999-10-01 | 2001-04-12 | The University Of North Carolina At Chapel Hill | Temperature-sensitive regulation of viral vector production |
| US7208315B2 (en) | 2000-01-05 | 2007-04-24 | Fred Hutchinson Cancer Research Center | Compositions and methods for efficient AAV vector production |
| WO2001066782A1 (en) | 2000-03-03 | 2001-09-13 | The Board Of Trustees Of The Leland Stanford Junior University | Adeno-associated viral compositions and methods |
| CA2403704C (en) | 2000-03-23 | 2012-04-10 | Collaborative Technologies, Inc. | Method for preparing high pressure/high shear dispersions containing physiologically active ingredients |
| AU4445701A (en) * | 2000-03-24 | 2001-10-03 | Centre National De La Recherche Scientifique-Cnrs | Multiple human and mouse otoferlin isoforms |
| RS49646B (sr) | 2000-07-04 | 2007-09-21 | Slobodan Arsenijević | Instrument za ubrizgavanje fluida i dilataciona sonda za uvođenje u telesne šupljine |
| FR2811561B1 (fr) | 2000-07-13 | 2003-03-21 | Oreal | Composition, notamment cosmetique, renfermant la dhea et/ou un precurseur ou derive chimique ou biologique de celle-ci, et un inhibiteur de metalloproteinase |
| US6329181B1 (en) | 2000-08-07 | 2001-12-11 | Neurologix, Inc. | Helper functions for recombinant vector production |
| US6593123B1 (en) | 2000-08-07 | 2003-07-15 | Avigen, Inc. | Large-scale recombinant adeno-associated virus (rAAV) production and purification |
| US20040048836A1 (en) | 2001-03-23 | 2004-03-11 | Wilmott James M | Method for preparing high pressure/ high shear dispersions containing physiologically active ingredients |
| EP1377255A4 (en) | 2001-03-30 | 2008-11-19 | Color Access Inc | NEW NANOEMULSIONS |
| KR100463167B1 (ko) | 2001-04-13 | 2004-12-23 | 주식회사 태평양 | 고분자 나노입자를 이용한 경피흡수제 및 이를 함유한외용제 조성물 |
| EP2545937A1 (en) | 2001-06-05 | 2013-01-16 | The Regents Of The University Of Michigan | Nanoemulsion vaccines |
| EP1427835B1 (en) | 2001-08-08 | 2016-01-20 | The Trustees of the University of Pennsylvania | Method for purification of viral vectors having proteins which bind sialic acid |
| US20040115159A1 (en) | 2002-03-29 | 2004-06-17 | Tadlock Charles C | Novel nanoemulsions |
| US7071172B2 (en) | 2002-04-30 | 2006-07-04 | The University Of North Carolina At Chapel Hill | Secretion signal vectors |
| US7419817B2 (en) | 2002-05-17 | 2008-09-02 | The United States Of America As Represented By The Secretary Department Of Health And Human Services, Nih. | Scalable purification of AAV2, AAV4 or AAV5 using ion-exchange chromatography |
| ATE389675T1 (de) | 2002-09-12 | 2008-04-15 | 3M Innovative Properties Co | Fluorelastomere mit niedertemperatureigenschaften und lösungsmittelbeständigkeit |
| US7329688B2 (en) | 2002-12-17 | 2008-02-12 | Soft Gel Technologies, Inc. | Natural vitamin E compositions with superior antioxidant potency |
| JP4559429B2 (ja) | 2003-05-21 | 2010-10-06 | ジェンザイム・コーポレーション | 空キャプシドを実質的に含まない組換えaavビリオン調製物を生成するための方法 |
| EP1633322A2 (en) | 2003-06-04 | 2006-03-15 | Nanobio Corporation | Compositions for inactivating pathogenic microorganisms, methods of making the compositions, and methods of use thereof |
| WO2005009287A2 (en) | 2003-07-21 | 2005-02-03 | University Of Maryland, Baltimore | Drug delivery to the inner ear and methods of using same |
| US20060151899A1 (en) | 2003-08-06 | 2006-07-13 | Akira Kato | Process for producing drug ultramicroparticle and apparatus therefor |
| EP1510206A1 (en) | 2003-08-29 | 2005-03-02 | Novagali Pharma SA | Self-nanoemulsifying oily formulation for the administration of poorly water-soluble drugs |
| CA2543722C (en) | 2003-10-29 | 2011-01-04 | Sonus Pharmaceuticals, Inc. | Tocopherol-modified therapeutic drug compounds |
| US7557197B2 (en) | 2004-01-28 | 2009-07-07 | Oregon Health & Science University | Human soluble neuropilin-1 primary polyadenylation signal and uses thereof |
| MXPA06009529A (es) | 2004-02-23 | 2007-04-10 | Texas A & M Univ Sys | Composiciones antioxidantes y metodos para el uso de las mismas. |
| US7419497B2 (en) | 2004-04-21 | 2008-09-02 | Acclarent, Inc. | Methods for treating ethmoid disease |
| ES2932278T3 (es) | 2004-06-01 | 2023-01-17 | Genzyme Corp | Composiciones y métodos para prevenir la agregación del vector AAV |
| US20050281786A1 (en) | 2004-06-18 | 2005-12-22 | David Poulsen | AAV mediated gene delivery to cochlear cells |
| WO2006012414A2 (en) | 2004-07-20 | 2006-02-02 | Critical Therapeutics, Inc. | Novel polyadenylation signal for use in expression vectors |
| US8591457B2 (en) | 2005-08-10 | 2013-11-26 | Alza Corporation | Method for making a needle-free jet injection drug delivery device |
| PT3272872T (pt) | 2005-10-20 | 2020-06-26 | Uniqure Ip Bv | Vetores aav melhorados produzidos em células de insetos |
| CN101528916B (zh) | 2006-04-28 | 2013-09-04 | 宾夕法尼亚大学托管会 | 规模可调的aav生产方法 |
| US7851196B2 (en) | 2006-05-01 | 2010-12-14 | The Regents Of The University Of California | Methods for purifying adeno-associated virus particles |
| WO2007148971A2 (en) | 2006-06-21 | 2007-12-27 | Amsterdam Molecular Therapeutics B.V. | Vectors with modified initiation codon for the translation of aav-rep78 useful for production of aav in insect cells |
| US20080065002A1 (en) | 2006-09-07 | 2008-03-13 | Neurosystec Corporation | Catheter for Localized Drug Delivery and/or Electrical Stimulation |
| US8173792B2 (en) * | 2007-02-09 | 2012-05-08 | The Board Of Trustees Of The Leland Stanford Junior University | Method for regulating protein function in cells using synthetic small molecules |
| HUE029744T2 (en) | 2007-07-26 | 2017-04-28 | Uniqure Ip Bv | Baculoviral vectors comprising repeated coding sequences with differential codon biases |
| US20090042825A1 (en) | 2007-08-06 | 2009-02-12 | Majed Matar | Composition, method of preparation & application of concentrated formulations of condensed nucleic acids with a cationic lipopolymer |
| US8236557B2 (en) | 2008-05-28 | 2012-08-07 | University Of Missouri-Columbia | Hybrid-AAV vectors to deliver large gene expression cassette |
| CA2744976C (en) | 2008-11-28 | 2017-09-12 | Austria Wirtschaftsservice Gesellschaft Mbh | Artificial chromosome vector |
| JP5956331B2 (ja) | 2009-06-16 | 2016-07-27 | ジェンザイム・コーポレーション | 組換えaavベクターの改良された精製方法 |
| JP5697123B2 (ja) | 2009-07-27 | 2015-04-08 | 国立大学法人 千葉大学 | 酸性化ポリエチレンイミンを用いる細胞への核酸導入方法 |
| WO2011075838A1 (en) | 2009-12-21 | 2011-06-30 | Audigen Inc. | Method of treating or preventing hearing loss |
| EP2529020B1 (en) | 2010-01-28 | 2018-04-25 | The Children's Hospital of Philadelphia | A scalable manufacturing platform for viral vector purification and viral vectors so purified for use in gene therapy |
| EP2545165B1 (en) | 2010-03-11 | 2020-07-29 | uniQure IP B.V. | Mutated rep encoding sequences for use in aav production |
| EP2605761A1 (fr) | 2010-08-19 | 2013-06-26 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Dispositif implantable dans l'os temporal pour administrer un produit et prothèse auditive pourvue d'un tel dispositif. |
| EP2500434A1 (en) | 2011-03-12 | 2012-09-19 | Association Institut de Myologie | Capsid-free AAV vectors, compositions, and methods for vector production and gene delivery |
| US8852165B2 (en) | 2011-06-16 | 2014-10-07 | II Edward G. Mackay | Endoluminal drug delivery devices and methods |
| EP2771455B1 (en) | 2011-10-28 | 2016-10-05 | The University of North Carolina At Chapel Hill | Cell line for production of adeno-associated virus |
| WO2013075008A1 (en) | 2011-11-16 | 2013-05-23 | University Of Florida Research Foundation Inc. | Aav dual vector systems for gene therapy |
| BR112014020325A2 (pt) | 2012-02-17 | 2017-08-08 | Childrens Hospital Philadelphia | composições de vetor do aav e métodos para a transferência de gene para as células, órgãos e tecidos |
| US11332719B2 (en) | 2013-03-15 | 2022-05-17 | The Broad Institute, Inc. | Recombinant virus and preparations thereof |
| JP2016517278A (ja) * | 2013-03-15 | 2016-06-16 | ザ・チルドレンズ・ホスピタル・オブ・フィラデルフィアThe Children’S Hospital Of Philadelphia | スタッファー/フィラーポリヌクレオチド配列を含むベクターおよびその使用方法 |
| DK2986635T3 (en) * | 2013-04-18 | 2019-01-28 | Fond Telethon | EFFECTIVE DELIVERY OF BIG GENES THROUGH DUAL-AAV VECTORS |
| US11078464B2 (en) | 2013-08-30 | 2021-08-03 | Amgen Inc. | High titer recombinant AAV vector production in adherent and suspension cells |
| HUE052676T2 (hu) | 2013-10-11 | 2021-05-28 | Massachusetts Eye & Ear Infirmary | Eljárások õsi vírusszekvenciák elõrejelzésére és alkalmazásaik |
| WO2015137802A1 (en) | 2014-03-10 | 2015-09-17 | Uniqure Ip B.V. | Further improved aav vectors produced in insect cells |
| US10526583B2 (en) | 2014-07-02 | 2020-01-07 | University Of Florida Research Foundation, Incorporated | Compositions and methods for purifying recombinant adeno-associated virus |
| SG11201704919SA (en) | 2015-01-13 | 2017-07-28 | Alfa Wassermann Inc | Methods of purifying adeno-associated virus (aav) and/or recombinant adeno-associated virus (raav) |
| EP3054006A1 (en) | 2015-02-09 | 2016-08-10 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Recombinant adeno-associated virus particle purification with multiple-step anion exchange chromatography |
| US10751385B2 (en) | 2015-02-20 | 2020-08-25 | Institut Pasteur | Prevention and/or treatment of hearing loss or impairment |
| US20180043034A1 (en) | 2015-03-06 | 2018-02-15 | Massachusetts Eye And Ear Infirmary | Gene augmentation therapies for inherited retinal degeneration caused by mutations in the prpf31 gene |
| EP4134375A1 (en) | 2015-07-30 | 2023-02-15 | Massachusetts Eye & Ear Infirmary | Ancestral adeno associated virus sequences and uses thereof |
| EP3384015A4 (en) | 2015-12-01 | 2019-05-29 | Spark Therapeutics, Inc. | SCALABLE PROCESS FOR THE PREPARATION OF A RECOMBINANT ADENO ASSOCIATED VIRAL VECTOR IN A SERUM-FREE SUSPENSION CELL CULTURE SYSTEM SUITABLE FOR THE CLINICAL APPLICATION |
| CA3007476A1 (en) | 2015-12-11 | 2017-06-15 | Massachusetts Eye And Ear Infirmary | Materials and methods for delivering nucleic acids to cochlear and vestibular cells |
| EP3393522B1 (en) | 2015-12-22 | 2021-07-07 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Improved hybrid dual recombinant aav vector systems for gene therapy |
| CN109219439B (zh) | 2016-01-29 | 2022-09-20 | 马萨诸塞眼科耳科诊所 | 内耳支持细胞的扩增和分化及其使用方法 |
| WO2017136764A1 (en) | 2016-02-05 | 2017-08-10 | The General Hospital Corporation | Hybrid system for efficient gene delivery to cells of the inner ear |
| EP3474941A1 (en) | 2016-06-22 | 2019-05-01 | The Charles Stark Draper Laboratory, Inc. | A system for inner ear drug delivery via trans-round window membrane injection |
| GB201612248D0 (en) | 2016-07-14 | 2016-08-31 | Puridify Ltd | New process |
| AU2017299779B2 (en) | 2016-07-21 | 2021-12-02 | Spark Therapeutics, Inc. | Scalable high recovery methods for producing high yield recombinant adeno-associated viral (rAAV) vector and recombinant adeno-associated viral (rAAV) vectors produced thereby |
| JP6994018B2 (ja) | 2016-07-26 | 2022-01-14 | バイオマリン ファーマシューティカル インコーポレイテッド | 新規アデノ随伴ウイルスキャプシドタンパク質 |
| PL3535388T3 (pl) | 2016-11-04 | 2023-08-14 | Takeda Pharmaceutical Company Limited | Sposoby oczyszczania wirusów związanych z adenowirusami |
| US10626376B2 (en) | 2016-11-14 | 2020-04-21 | St. Jude Children's Research Hospital | Method for isolating and purifying adeno-associated virus particles using salt |
| CN111698975A (zh) | 2017-02-06 | 2020-09-22 | 儿童医疗中心有限公司 | 将核酸递送至耳蜗和前庭细胞的材料和方法 |
| EP3618839A4 (en) | 2017-05-05 | 2021-06-09 | Voyager Therapeutics, Inc. | COMPOSITIONS AND METHODS OF TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS) |
| US12359221B2 (en) * | 2017-05-05 | 2025-07-15 | The Regents Of The University Of California | Compositions and methods for expressing otoferlin |
| US20200270635A1 (en) | 2017-05-05 | 2020-08-27 | Voyager Therapeutics, Inc. | Modulatory polynucleotides |
| MX2019013172A (es) | 2017-05-05 | 2020-09-07 | Voyager Therapeutics Inc | Composiciones y metodos para tratar la enfermedad de huntington. |
| JOP20190269A1 (ar) | 2017-06-15 | 2019-11-20 | Voyager Therapeutics Inc | بولي نوكليوتيدات aadc لعلاج مرض باركنسون |
| US11512327B2 (en) | 2017-08-03 | 2022-11-29 | Voyager Therapeutics, Inc. | Compositions and methods for delivery of AAV |
| WO2019084145A1 (en) | 2017-10-25 | 2019-05-02 | The Charles Stark Draper Laboratory Inc. | APPARATUS AND METHOD FOR DRUG DELIVERY ACROSS THE ROUND WINDOW MEMBRANE |
| EP3740581A4 (en) | 2018-01-16 | 2021-10-27 | CLS Therapeutics Limited | TREATMENT OF DISEASES BY LIVER EXPRESSION OF AN ENZYME WITH DESOXYRIBONUCLEASE (DNASE) ACTIVITY |
| BR112020016059A2 (pt) | 2018-02-09 | 2020-12-08 | Decibel Therapeutics, Inc. | Composições farmacêuticas hipertônicas contendo um agente quimioprotetor anti-platina |
| DE102018103924A1 (de) | 2018-02-21 | 2019-08-22 | Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts, Universitätsmedizin | Gentherapeutische Behandlung von Schwerhörigkeit |
| IL325122A (en) | 2018-02-22 | 2026-02-01 | Akouos Inc | Compositions and methods for treating non-age-related hearing impairment in humans |
| JP7430652B2 (ja) | 2018-03-05 | 2024-02-13 | ザ チルドレンズ メディカル センター コーポレーション | 蝸牛および前庭細胞に核酸を送達するための組成物および方法 |
| US11660353B2 (en) | 2018-04-27 | 2023-05-30 | Decibel Therapeutics, Inc. | Compositions and methods for treating sensorineural hearing loss using otoferlin dual vector systems |
| CN112703016B (zh) | 2018-04-27 | 2024-11-22 | 分贝治疗公司 | 肌球蛋白15启动子及其用途 |
| WO2019222329A1 (en) | 2018-05-15 | 2019-11-21 | Voyager Therapeutics, Inc. | Compositions and methods for delivery of aav |
| CN112424359A (zh) | 2018-05-15 | 2021-02-26 | 沃雅戈治疗公司 | 用于治疗帕金森氏病的组合物和方法 |
| MX2020013953A (es) | 2018-07-11 | 2021-03-09 | Takeda Pharmaceuticals Co | Composiciones de virus adenoasociado (aav). |
| WO2020023612A1 (en) | 2018-07-24 | 2020-01-30 | Voyager Therapeutics, Inc. | Systems and methods for producing gene therapy formulations |
| US12491223B2 (en) | 2018-09-27 | 2025-12-09 | Akouos, Inc. | Method for treating an auditory neuropathy spectrum disorder |
| US12534739B2 (en) | 2018-10-11 | 2026-01-27 | Decibel Therapeutics, Inc. | AAV1 vectors and uses thereof for treatment of otic indications |
| WO2020093018A1 (en) | 2018-11-01 | 2020-05-07 | University Of Florida Research Foundation, Incorporated | A codon optimized otoferlin aav dual vector gene therapy |
| CN113853437A (zh) | 2018-11-07 | 2021-12-28 | 阿库斯股份有限公司 | 腺相关病毒载体用于在内耳中的毛细胞和支持细胞中校正基因缺陷/表达蛋白质的用途 |
| CN113924109A (zh) | 2019-01-18 | 2022-01-11 | 巴斯德研究所 | Aav介导的基因疗法恢复耳畸蛋白基因 |
| CN110437317B (zh) | 2019-01-30 | 2023-05-02 | 上海科技大学 | 具有变异衣壳蛋白的腺相关病毒及其用途 |
| WO2020163761A1 (en) | 2019-02-08 | 2020-08-13 | Decibel Therapeutics, Inc. | Myosin 15 promoters and uses thereof |
| EP3921032A4 (en) | 2019-02-08 | 2022-11-30 | Decibel Therapeutics, Inc. | COMPOSITIONS AND METHODS FOR TREATMENT OF SENSORINEURAL HEARING LOSS USING OTOFERLIN DOUBLE VECTOR SYSTEMS |
| WO2020223933A1 (zh) | 2019-05-08 | 2020-11-12 | 中国科学院脑科学与智能技术卓越创新中心 | 高效感染支持细胞的aav突变体 |
| JP7713130B2 (ja) | 2019-09-30 | 2025-07-25 | イーライ リリー アンド カンパニー | 遺伝性難聴の処置のためのアデノ随伴ウイルス(aav)システム |
| AU2020366531A1 (en) | 2019-10-18 | 2022-05-26 | Research Institute At Nationwide Children's Hospital | Gene therapy targeting cochlear cells |
| TWI896570B (zh) | 2019-10-30 | 2025-09-11 | 美商迪賽博治療公司 | 使用耳畸蛋白雙載體系統治療感覺神經性聽力損失之組合物及方法 |
| EP4054653A4 (en) | 2019-11-04 | 2023-11-29 | Decibel Therapeutics, Inc. | PROMOTERS OF COCHLEAR EXTERNAL HAIR CELLS AND THEIR USES |
| CA3157799A1 (en) | 2019-11-11 | 2021-05-20 | Salk Institute For Biological Studies | Compositions and methods for high-efficiency recombination of rna molecules |
| WO2021150850A1 (en) | 2020-01-24 | 2021-07-29 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Svcs. | Adeno-associated viruses and their uses for inner ear therapy |
| EP4100533A1 (en) | 2020-02-07 | 2022-12-14 | University of Rochester | Ribozyme-mediated rna assembly and expression |
| US20230090778A1 (en) | 2020-02-07 | 2023-03-23 | The Children's Medical Center Corporation | Large gene vectors and delivery and uses thereof |
| CA3168055A1 (en) | 2020-02-21 | 2021-08-26 | Emmanuel John Simons | Compositions and methods for treating non-age-associated hearing impairment in a human subject |
| WO2021183825A1 (en) | 2020-03-12 | 2021-09-16 | California Institute Of Technology | Adeno-associated viral capsids with expanded sizes |
| CN111349148A (zh) | 2020-03-13 | 2020-06-30 | 辉大(上海)生物科技有限公司 | 一种腺相关病毒载体及其用途 |
| EP3885440A1 (en) | 2020-03-26 | 2021-09-29 | Splicebio, S.L. | Split inteins and their uses |
| WO2022056440A1 (en) | 2020-09-14 | 2022-03-17 | President And Fellows Of Harvard College | Dual-aav vector delivery of pcdh15 and uses thereof |
| MX2023005344A (es) | 2020-11-06 | 2023-12-07 | Lilly Co Eli | Polipéptidos de la cápside variante del virus adenoasociado (aav) y su terapéutico génica para el tratamiento de la pérdida de audición. |
| EP4008788A1 (en) | 2020-12-03 | 2022-06-08 | Medizinische Hochschule Hannover | Lentiviral vector technology for inner ear gene therapy |
| KR20240004253A (ko) | 2021-02-19 | 2024-01-11 | 데시벨 테라퓨틱스, 인크. | 오토펄린 듀얼 벡터 시스템을 사용한 감각신경성 난청을 치료하기 위한 방법 |
| US20240226331A9 (en) | 2021-02-22 | 2024-07-11 | Decibel Therapeutics, Inc. | Methods and compositions for reducing nucleic acid vector-induced toxicity in the inner ear |
| AU2022264006A1 (en) | 2021-04-27 | 2023-11-02 | The Children's Hospital Of Philadelphia | Adeno-associated viral vectors for transduction of cochlea |
| WO2023283962A1 (en) | 2021-07-16 | 2023-01-19 | Huigene Therapeutics Co., Ltd. | Modified aav capsid for gene therapy and methods thereof |
| CN113337507B (zh) | 2021-08-05 | 2021-11-12 | 首都医科大学附属北京友谊医院 | Otof 1273 (C>T)基因定点突变的耳聋小鼠模型的构建方法及其应用 |
| JP2024534991A (ja) | 2021-09-10 | 2024-09-26 | インスティチュート パスツール | オトフェリンのアイソフォーム5をコードする二重組換えaav8ベクター系およびその使用 |
| US20250099619A1 (en) | 2021-12-06 | 2025-03-27 | Juntendo Educational Foundation | Modified adeno-associated virus vector |
| JP2025504263A (ja) | 2021-12-23 | 2025-02-10 | ユニバーシティ オブ ロチェスター | 内耳への薬剤の送達のためのcsf輸送経路 |
| CN117106824B (zh) | 2022-05-17 | 2025-09-02 | 上海佑音医药生物科技有限公司 | 一种治疗听力损伤的双载体系统及其应用 |
| US20230242942A1 (en) | 2022-05-17 | 2023-08-03 | Eye & Ent Hospital Of Fudan University | Dual-vector system for treating hearing impairment and use thereof |
| AR129387A1 (es) | 2022-05-19 | 2024-08-21 | Akouos Inc | Composiciones y métodos para el tratamiento de deficiencias auditivas no asociadas a la edad en un sujeto humano |
| WO2024151703A2 (en) | 2023-01-12 | 2024-07-18 | Ohio State Innovation Foundation | Gene therapy for treating hearing loss disorders |
| CN121002049A (zh) | 2023-02-17 | 2025-11-21 | 分贝治疗公司 | 用于施用耳畸蛋白双载体系统的方法和组合物 |
| CN120882872A (zh) | 2023-03-17 | 2025-10-31 | 罗切斯特大学 | 核酶介导的rna组装和表达 |
| CN118834869A (zh) | 2023-04-12 | 2024-10-25 | 上海玮美基因科技有限责任公司 | Senp6启动子及其用途 |
| CN121311586A (zh) | 2023-05-12 | 2026-01-09 | 苏州星奥拓维生物技术有限公司 | 耳蜗內毛细胞特异性启动子及其应用 |
| WO2024239226A1 (zh) | 2023-05-23 | 2024-11-28 | 苏州星奥拓维生物技术有限公司 | 耳蜗毛细胞特异性启动子及其用途 |
| WO2025003513A1 (en) | 2023-06-29 | 2025-01-02 | Katholieke Universiteit Leuven | Otoferlin gene transfer |
| CN116925239B (zh) | 2023-07-17 | 2024-10-18 | 苏州星奥拓维生物技术有限公司 | 双载体系统表达Otof基因的组合物和方法 |
| CN117305367A (zh) | 2023-08-21 | 2023-12-29 | 复旦大学附属眼耳鼻喉科医院 | 一种表达全长耳畸蛋白的双aav载体系统及其应用 |
| KR20260092437A (ko) | 2023-10-19 | 2026-06-18 | 유니버시티 오브 피츠버그-오브 더 커먼웰쓰 시스템 오브 하이어 에듀케이션 | 난청 및 전정 장애를 위한 유전자 요법 |
| AU2024397647A1 (en) | 2023-12-11 | 2026-06-25 | Akouos, Inc. | Compositions and methods for treating hearing loss in a human subject having a defective otoferlin gene |
| CN118931896A (zh) | 2024-04-09 | 2024-11-12 | 复旦大学附属眼耳鼻喉科医院 | 一种用于修复OTOF基因p.Q829X突变的单碱基编辑系统及其应用 |
| CN118667036B (zh) | 2024-08-20 | 2025-01-10 | 上海玮美基因科技有限责任公司 | 一种融合型腺相关病毒衣壳蛋白、腺相关病毒及其应用 |
| CN120098142A (zh) | 2025-03-06 | 2025-06-06 | 东南大学 | 腺嘌呤碱基编辑器用于dfnb9听力损失修复 |
-
2019
- 2019-02-21 IL IL325122A patent/IL325122A/en unknown
- 2019-02-21 IL IL276764A patent/IL276764B2/en unknown
- 2019-02-22 CN CN201980026498.XA patent/CN112020561A/zh active Pending
- 2019-02-22 MX MX2020008763A patent/MX428733B/es unknown
- 2019-02-22 JP JP2020544478A patent/JP7408228B2/ja active Active
- 2019-02-22 SG SG11202007491UA patent/SG11202007491UA/en unknown
- 2019-02-22 WO PCT/US2019/019268 patent/WO2019165292A1/en not_active Ceased
- 2019-02-22 MA MA051918A patent/MA51918A/fr unknown
- 2019-02-22 AU AU2019224121A patent/AU2019224121B2/en active Active
- 2019-02-22 BR BR112020016919-6A patent/BR112020016919A2/pt unknown
- 2019-02-22 CA CA3091676A patent/CA3091676A1/en active Pending
- 2019-02-22 KR KR1020257043517A patent/KR20260015297A/ko active Pending
- 2019-02-22 EA EA202091995A patent/EA202091995A1/ru unknown
- 2019-02-22 US US16/971,922 patent/US20200390905A1/en not_active Abandoned
- 2019-02-22 KR KR1020207027137A patent/KR102907773B1/ko active Active
- 2019-02-22 EP EP19757886.7A patent/EP3755805A4/en active Pending
-
2020
- 2020-08-21 MX MX2025012429A patent/MX2025012429A/es unknown
- 2020-08-21 CL CL2020002161A patent/CL2020002161A1/es unknown
-
2021
- 2021-04-08 US US17/225,621 patent/US12673116B2/en active Active
-
2023
- 2023-12-15 JP JP2023212464A patent/JP2024023691A/ja active Pending
-
2025
- 2025-11-05 AU AU2025263792A patent/AU2025263792A1/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016139321A1 (en) * | 2015-03-03 | 2016-09-09 | Fondazione Telethon | Multiple vector system and uses thereof |
| WO2018039375A1 (en) * | 2016-08-23 | 2018-03-01 | Akouos, Inc. | Compositions and methods for treating non-age-associated hearing impairment in a human subject |
Non-Patent Citations (1)
| Title |
|---|
| ALEMI ET AL: "AOS research grant: Restoration of Hearing in the Otoferliu Knockout Mouse using Viral Gene Therapy", 145TH ANNUAL MEETING, 21-22 APRIL 2012; AMERICAN OTOLOGICAL SOCIETY, INC, US, vol. 145th, 21 April 2012, pages 68. * |
Also Published As
| Publication number | Publication date |
|---|---|
| IL325122A (en) | 2026-02-01 |
| BR112020016919A2 (pt) | 2020-12-15 |
| IL276764B2 (en) | 2026-05-01 |
| AU2019224121A1 (en) | 2020-08-27 |
| MX428733B (es) | 2025-11-13 |
| CL2020002161A1 (es) | 2021-01-08 |
| KR20260015297A (ko) | 2026-02-02 |
| EP3755805A4 (en) | 2022-01-19 |
| WO2019165292A1 (en) | 2019-08-29 |
| MA51918A (fr) | 2020-12-30 |
| EP3755805A1 (en) | 2020-12-30 |
| JP7408228B2 (ja) | 2024-01-05 |
| MX2020008763A (es) | 2021-02-15 |
| IL276764A (en) | 2020-10-29 |
| EA202091995A1 (ru) | 2021-03-30 |
| MX2025012429A (es) | 2025-11-03 |
| AU2025263792A1 (en) | 2025-11-27 |
| IL276764B1 (en) | 2026-01-01 |
| US20220040327A1 (en) | 2022-02-10 |
| JP2021513863A (ja) | 2021-06-03 |
| US12673116B2 (en) | 2026-07-07 |
| KR20200126997A (ko) | 2020-11-09 |
| CA3091676A1 (en) | 2019-08-29 |
| US20200390905A1 (en) | 2020-12-17 |
| SG11202007491UA (en) | 2020-09-29 |
| CN112020561A (zh) | 2020-12-01 |
| KR102907773B1 (ko) | 2026-01-06 |
| JP2024023691A (ja) | 2024-02-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12264317B2 (en) | Compositions and methods for treating non-age-associated hearing impairment in a human subject | |
| US20220040327A1 (en) | Compositions and methods for treating non-age-associated hearing impairment in a human subject | |
| US12077773B2 (en) | Compositions and methods for treating non-age-associated hearing impairment in a human subject | |
| HK40098362A (en) | Compositions and methods for treating non-age-associated hearing impairment in a human subject | |
| EA052823B1 (ru) | Композиции и способы лечения не связанного с возрастом нарушения слуха у субъекта-человека |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGA | Letters patent sealed or granted (standard patent) |